EW Edwards Lifesciences Corporation
USHealthcareAs of 2026-10-08
Why EW matters now
Edwards Lifesciences Corporation (EW) is a US stock in Healthcare. The latest InvestLog snapshot shows $84.22 with -1.82% on the session and $48.49B in market capitalization; recent performance reads 1-month +6.33% and YTD +2.48%.
The latest financial table shown here is Q1 2026, with revenue of $1.65B, net income of $380.7M, and EPS of $0.66. Investors can compare that operating picture with valuation signals such as P/E 42.26 and FCF yield 2.2%.
InvestLog's latest related AI research is a Rating Change note titled "Barclays initiates coverage of EW with Overweight". The latest indexable market news headline is "Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $95.00; recent insider activity includes Zovighian Bernard J filing S-Sale; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
42.26
PEG
—
P/B
4.90
P/S
7.98
EV/EBITDA
34.18
DCF Value
$62.63
FCF Yield
2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
78.0%
Operating Margin
27.6%
Net Margin
17.3%
ROE
10.6%
ROA
8.2%
ROIC
12.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.65B | $380.7M | $0.66 |
| Q4 2025 | $1.57B | $91.2M | $0.16 |
| FY 2025 | $6.07B | $1.07B | $1.83 |
| Q3 2025 | $1.55B | $291.1M | $0.50 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$96.55
Target (Median)
$95.00
Target Range
$85.00 - $110.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Barclays initiates coverage of EW with OverweightBarclays 首次覆盖 爱德华兹生命科学公司 (EW)，初始评级 增持（Overweight）
On 2026-10-06, Barclays initiated coverage of EW with a Overweight rating.Barclays 于 2026-10-06 首次覆盖 EW，初始评级为 增持（Overweight）。
EW receives FDA approval for AUTUS ValveEdwards Lifesciences Corporation（EW）的 AUTUS Valve 获美国 FDA 批准
EW receives FDA approval for AUTUS Valve.Edwards Lifesciences Corporation（EW）的 AUTUS Valve 获美国 FDA 批准。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.87
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.